Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype

Clinical Breast Cancer

Volumn 11, Issue 5, 2011, Pages 325-331

  Theriault, Rachel L ^a   Litton, Jennifer K ^a   Mittendorf, Elizabeth A ^a   Chen, Huiqin ^a   Meric Bernstam, Funda ^a   Chavez MacGregor, Mariana ^a   Morrow, Phuong K ^a   Woodward, Wendy A ^a   Sahin, Aysegul ^a   Hortobagyi, Gabriel N ^a   Gonzalez Angulo, Ana M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Distant recurrence free survival; HER2; Hormone receptor; Recurrence free survival; Triple negative breast cancer

Indexed keywords

HORMONE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOLOGY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MENOPAUSE; ONCOGENE NEU; OVERALL SURVIVAL; RACE; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; TRIPLE NEGATIVE BREAST CANCER; AGE; BREAST TUMOR; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REGISTER; SURVIVAL; UNITED STATES;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; REGISTRIES; SURVIVAL ANALYSIS; TEXAS;

EID: 84855746053     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.05.002     Document Type: Article

References (22)

1. Goyal A, Newcombe RG, Mansel RE, et al: Sentinel lymph node biopsy in patients with multifocal breast cancer. Eur J Surg Oncol 2004; 30: 475-9. (Pubitemid 38701866)
2. American Cancer Society: Cancer Facts & Figures 2010 [Web site]. Available at: www.cancer.gov. Accessed: October 24, 2010
3. Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy. Cancer 2005; 103: 689-95.
4. Fisher B, Redmond C, Dimitrov NV, et al: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with nodenegative breast cancer who have estrogen-receptor-negative tumors. New Engl J Med 1989; 320: 473-8. (Pubitemid 19062521)
5. Fisher B, Dignam J, Mamounas EP, et al: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptornegative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996; 14: 1982-92.
6. Fisher B, Anderson S, Tan-Chiu E, et al: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 19: 931-42. (Pubitemid 32176267)
7. Fisher B, Jeong J-H, Anderson S, et al: Treatment of axillary lymph nodenegative, estrogen receptor-negative breast cancer: updated findings from national surgical adjuvant breast and bowel project clinical trials. J Natl Cancer Inst 2004; 96: 1823-31. (Pubitemid 40089466)
8. Gonzalez-Angulo AM, Broglio K, Kau SW, et al. Women age < 35 years with primary breast carcinoma. Cancer 2005; 103: 2466-72.
9. Nixon AJ, Neuberg D, Hayes DF, et al: Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994; 12: 888-94. (Pubitemid 24145313)
10. Gnerlich JL, Deshpande AD, Jeffe DB, et al: Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg 2009; 208: 341-7.
11. Kwon JH, Kim YJ, Lee KW, et al: Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. BMC Cancer 2010; 10: 557.
12. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009; 27: 5700-6.
13. Amar S, McCullough AE, Tan W, et al: Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist 2010; 15: 1043-9.
14. Albert JM, Gonzalez-Angulo AM, Guray M, et al: Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys 2010; 77: 1296-302.
15. Park YH, Kim ST, Cho EY, et al: A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat 2010; 119: 653-61.
16. Joensuu H, Isola J, Lundin M, et al: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003; 9: 923-30. (Pubitemid 36323694)
17. Black M, Speer F: Nuclear structure in cancer tissue. Surg Gynecol Obbstet 1982; 105: 97-102.
18. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-20. (Pubitemid 43290919)
19. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72. (Pubitemid 41464705)
20. Slamon D, Eiermann W, Robert N, et al: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and traztuzumab with docetaxel, carboplatin and trazuzumab in HER2/new positive early breast cancer patients Presented at the 29th annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006.
21. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84. (Pubitemid 41464706)
22. Viani GA, Afonso SL, Stefano EJ, et al: Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007; 7: 153.